Nabriva therapeutics appoints CEO
This article was originally published in Scrip
Biotechnology company Nabriva Therapeutics, which is developing a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative pathogens, has named Dr Colin Broom chief executive officer. Prior to joining Vienna-based Nabriva Dr Broom was chief scientific officer at ViroPharma, which was acquired by Shire in January 2014. He succeeds Ralf Schmid, who will remain at the company as a member of the executive management team and will move to the role of chief financial officer and chief operating officer.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.